true, but Bell Potter has maintained their 42 cent valuation.
BP suggest the Australian market post TGA could deliver 90 treatments in the first year.
HDE approval this year could bring the same number in US (my assumption not theirs)
And private payers could bring the same in UK and Germany (again, thats me)
So, while there are assumptions there, they aren't unachievable. If TGA approve and FDA approve HDE, that's a possible 270 treatments pa.
BP estimate 290 sales for the 21-22 year, so I guess we are similar.
The RCT will still happen, sure, but if they are selling 270-290 pa, approx 6 mill revenue, I think the company will be in much better situation not to mention share price. And as Nigel mentioned in the company update the RCT becomes a marketing and education tool while it is running.
OSL Price at posting:
9.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)